Today, a "darling" company in the media thanks to new obesity drugs and other good news hitting the media airwaves is selling off. In fact, its having its worst day relative to its sector peers in many years.
For the longest time, investors in the United States have been rewarded for their home country bias and their overexposure to large-caps and growth stocks.